Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DIAAF breaks .0017 and she'll go to .003
Diaaf .0016 here again and will go fast
DIAAF will run bigtime soon imo
DIAAF to a penny boys and girls
diaaf product for today & tomorrow
DIAAF great news
Have a great weekend all
BHUB chart looks real good
Good morning L II please
Xechem's Subsidiary Receives 2nd Phase Loan Approval from NEXIM Bank
PrintE-mailDisable live quotesRSSDigg itDel.icio.us
Last Update: 4:03 PM ET Mar 29, 2007
NEW BRUNSWICK, N.J., Mar 29, 2007 (BUSINESS WIRE) -- Xechem International, Inc. (XKEM : XKEM
News , chart , profile , more
Last:
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
XKEM, , ) announced today that its subsidiary Xechem Pharmaceuticals Nigeria Ltd. received final approval from the Nigerian Export-Import ("NEXIM") Bank on March 28, 2007 for an additional loan of N350 Million Naira (approximately $2.6 million US Dollars).
Dr. Ramesh C. Pandey, the Chairman and CEO, stated, "The proceeds of this loan, which we expect to receive in the coming days, will allow us to place the ongoing construction of our new full scale manufacturing facility on the highest priority level. We are going to work very closely with our contractors and our partners at the Sheda Science and Technology Complex (SHESTCO) property to facilitate as rapid a completion of the construction as possible."
"We are very grateful to all who have worked so hard to make this happen," Dr. Pandey continued, "and recognize the level of commitment the NEXIM Bank has made to help assure the people of Nigeria and ultimately the world that this important anti-sickling drug, discovered by a Nigerian research team at the National Institute for Research and Development (NIPRD), will be made available to all who need it."
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN(TM).
After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN(TM) is being marketed in Nigeria since July 6th, 2007 on a limited basis. NICOSAN(TM) has Orphan Drug Designation in the US and EU countries.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its currently proposed bank financings; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria's pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulatory risks; and (v) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.
SOURCE: Xechem International, Inc.
Xechem International, Inc. Stephen Burg, 707-425-8855 Director Copyright Business Wire 2007
BHUB ut'ng again
Thank you for the L II
level II pleas thanks
VRA morning gapper
VRA GBVS
GOT GBVS?
Huge news for CHNW
xechem CEO, In Wide-Ranging UPI Interview, Discusses for-Profit Model for Delivering Critically-Needed Drugs for African Market
Business Wire - January 03, 2007 10:03
Dr. Ramesh Pandey, CBS/MarketWatch Readers Choice CEO Of Year, Lays out Plans for $250+ Million in Sales of New Sickle Cell Drug
NEW BRUNSWICK, N.J., Jan 03, 2007 (BUSINESS WIRE) -- Xechem International, Inc. (OTCBB: XKEM), Dr. Ramesh Pandey, president and CEO of Xechem International, was interviewed at length by United Press International (UPI) recently on his plans to manufacture and market the first new treatment for Sickle Cell Disease in decades in Nigeria. Sickle Cell Disease threatens the lives of 4 million Nigerians, as well as 80,000 Americans and many millions more worldwide.
The interview, which follows, can be found at:
http://www.upi.com/HealthBusiness/view.php?StoryID=20061221- 033418-3614r.(Due to the length of this URL, it may be necessary to copy and paste it into your Internet browser's URL address field. You may also need to remove an extra space in the URL if one exists.)
UPI Interview: Into Africa: Xechem CEO
WASHINGTON, Dec. 21 (UPI) -- United Press International interviewed Dr. Ramesh Pandey, an Indian-born medicinal chemist who founded his own company after years of working for large pharmaceutical companies, with this mission statement: make needed drugs that no one else would make.
More than 20 years later, Xechem, his New Jersey-based company, holds lucrative patents on drugs like paclitaxel, a cancer treatment derived from the Yew tree.
After a chance meeting with Nigerian officials, Xechem has opened one of the most state-of-the-art pharmaceutical plants in Africa. The factory churns out Nicosan, the first non-toxic treatment for sickle-cell anemia, a disease that afflicts about 16 million individuals primarily of African descent worldwide.
For his work, he has been awarded the Reader's Choice CBS/MarketWatch CEO of the Year award, and immortalized in a song written by Martin Luther King Jr.'s niece. But despite all this, he says, there is still more work to be done.
Q: How did you end up working on drugs for orphan diseases?
A: I was working at Abbott Laboratories, working on antibiotics and cancer treatments that cost $3 million, $4 million or $5 million per kilogram. Then I was approached by a company called Lyphomed to help them develop a generic version of the drug vancomycin (an antibiotic used to treat severe infections). The only company making the drug was Eli Lilly, and their patent had been expired for five years. Nobody in China, India, anywhere, was making the drug.
I wasn't sure at first if I could make the drug, but after three and a half years we developed a version. We founded Xechem and the charter was to make drugs not available anywhere else on the market. We put our generic into production in Copenhagen and Japan. We made our money back in less than two weeks. My entire life changed.
Q: You bought out Xechem from its parent company in 1990, but as the company prepared for its first public offering, an untimely patent extension granted to another firm sent the stock into freefall. Can you describe your meeting with a Nigerian delegation in search of a sickle-cell anemia drug that turned things around for you?
A: Until that time, I had no idea what sickle-cell disease was. I overheard someone from the delegation saying 'We have a drug for sickle-cell disease but nobody wants to put up money.' I said, 'I want it.' At the time, there was no non-toxic drug for the disease.
The Nigerians said 'Westerners come here, take things and never come back. Can you set up a factory here?' I went to Nigeria and saw there was a lot of opportunity there. I agreed to build a factory.
We are currently marketing the drug in Nigeria and we plan to bring the drug to the United States -- where 80,000 people have sickle-cell anemia -- to increase its credibility.
Q: Most of the attention goes to efforts to donate drugs to people in low-income countries. But you have built a successful model based on selling to the Nigerian market. How does it work?
A: Nigeria has a population of 130 million people. Like in every country, there are rich and poor people. It is very cheap to manufacture things there, and many people can afford to buy the treatment.
Right now, the problem is that demand for the drug is greater than what we can produce. Other countries have sent delegations to tour our factory.
Especially when the government is in the picture, I think it makes a lot of sense to develop things in those countries. We are making history. I think there's a tremendous opportunity to help people.
Q: What is it like to operate in Nigeria?
A: People have a very bad image of Nigeria and other African countries; we've helped to change that. If you come there, you can see that what we have built is as good as anywhere else. People will change their impression and say yes, things can be done in these countries.
One problem we have encountered is that often, once people are trained, they leave. We have decided to start classes at Nigerian universities to ensure a supply of trained workers.
(These countries) are looking for people like us who can help build. Criticism won't help anybody get anywhere.
Q: Where do you plan to market the drug next?
A: We expect sales of between $240 million and $288 million per year in Nigeria in the next three to five years. Then we plan to market the drug in all African countries because there are no other drugs on the market.
We also have orphan drug status in the United States and the European Union.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.
SOURCE: Xechem International, Inc.
Xechem International, Inc.
Stephen Burg, Director, 707-425-8855
Copyright Business Wire 2007
Dutton Associates Announces Investment Opinion: Pluristem Life Sciences Rating Raised to Speculative Buy by Dutton Associates
Business Wire - October 25, 2006 09:58
EL DORADO HILLS, Calif., Oct 25, 2006 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Pluristem Life Sciences (OTCBB:PLRS) raising its rating to Speculative Buy with a $.06 price target. The research note by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
Pluristem Life Systems, Inc. stock overhang from a previous overhang has been worked through and the common stock could now significantly appreciate as this selling pressure is reduced. Because we continue to be enamored by Pluristem's technology we have, therefore, revised our investment rating to Speculative Buy with a 12-month price target of $0.06.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $20,000 from the Company for 2 Research Reports with coverage commencing on 9/06/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
SOURCE: Pluristem Life Systems, Inc.
Dutton Associates
John M. Dutton, President, 916-941-8119
letstrade thanks for the heads up
Actually I am considering sending MO'Money to average down even more, but then I will have a gazillion shares what would i do with all that money when this hits .01, 02, 03.....
darn 4's crazy if you ask me... Sandy! where are you?
Volume is anemic, any thoughts? rumors?
Good morning everyone, I have a good feeling about today. Our chart looks ready to rock and roll. Just maybe we will have news today, had news on th 24th, 26th and maybe it is a pattern 28th...we shall see. No sell off is happening thats a great sign. Have a great day all.
Dart- That's a very nice looking chart.
whats that mean 911 trade? emergency?
They can keep on trying to pull us down but they will not be able to keep us down....
BKMP 7's starting to fly
BKMP 7's starting to fly
BKMP 7's starting to fly
This is like in the movie the The Good, the bad and the ugly....and the 7 represents Clint Eastwood The Terrific scene towards the end where three men have found the gold BKMP
commonnnn lucky 7'S
I just read the news and indeed its good 6's are flying
analyzethis I concur........ I added shares yesterday, I may wire more money to add again. US carrier news is around the corner IMO....
Mani and they very well should be saying that, why would anyone sell at this price. We can only go north from here
Huh? it is two separate sentences. I just find that when a stock is at the bottom, it is at the bottom because investors have become tired of waiting, their money seemingly disappearing as a pps goes down. THAT'S WHEN NEWS COMES, think about it, almost a month without news many have sold, one pr today and at any moment the news we have been waiting for appears and THEY MISS THE RUN.... or miss a few points. We have to be patient if we have done our DD we know that we have a company with a strong future. Be patient so that we do not become patients...
At least we finished at 6